GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
Terminated
- Conditions
- Basal Cell Carcinoma
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT01604252
- Locations
- 🇺🇸
Newport Dermatology and Laser Associates, Newport Beach, California, United States
🇺🇸Laser and Dermatologic Surgery Center, Chesterfield, Missouri, United States
🇺🇸Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT01602120
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇩🇪St. Franziskus Hospital, Munster, Germany
🇩🇪Universitatsklinikum Leipzig, Leipzig, Germany
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Completed
- Conditions
- Non-Small Cell Lung CancerGlioblastomaRenal Cell CancerBreast CancerColorectal Cancer
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT01598597
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01586195
- Locations
- 🇺🇸
Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Oncology Specialists, S.C., Park Ridge, Illinois, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT01582503
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01577173
A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01564251
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01562275
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01547546
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01546519
© Copyright 2025. All Rights Reserved by MedPath